{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '(e.g. patient able to swallow the apremilast tablets, blood', 'sampling).', 'Criteria for', 'General', 'Exclusion', 'Pregnant or breast-feeding women', 'Current or history of psychiatric disease that would interfere with', 'the ability to comply with the study protocol or give informed', 'consent', 'Patients known to have had a substance abuse (drug or alcohol)', 'problem within the previous 12 months', 'Individuals who are involved in the organization of the study', 'Patients who are in any way dependent on the investigator', 'Patients who are participating in a clinical study', 'Relatives, partner or staff of any clinical site personnel', 'Disease-related', 'Evidence of skin conditions (e.g. eczema) other than PPP /', 'psoriasis that would interfere with evaluations of the effect of', 'study medication on PPP or psoriasis.', 'Laboratory values available from routine blood test taken within', '8 weeks prior to screening with any of the following:', 'Serum creatinine >1.4 X upper limit of normal (ULN) for age', 'and gender', 'Estimated Glomerular Filtration Rate (eGFR) < 30', 'mL/min/1.73 m\u00b2 according to the CKD-EPI equation', 'Pustular psoriasis lesions on the part of body other than hands', 'or feet', 'Significant concurrent medical conditions at the time of', 'screening, including:', 'Risk factors for renal toxicity (renal inflammation)', 'Severe hepatic dysfunction', 'Unstable angina pectoris', 'Uncompensated congestive heart failure', 'Severe pulmonary disease requiring hospitalization or', 'supplemental oxygen therapy', 'Immunodeficiency disorders: primary or secondary', 'Known positive HIV test result, hepatitis B surface (HBS)', 'antigen or hepatitis C (HCV) test result', 'Uncontrolled Insulin-dependent diabetes mellitus', 'Cancer or history of cancer (except for resected cutaneous', 'basal cell or squamous cell carcinoma) in the last 5 years', 'Open cutaneous ulcers', 'Any condition that, in the judgment of the investigator, might', 'cause this study to be detrimental to the patient.', 'Medication-related', 'Ultraviolet B (UVB) therapy, topical steroids, topical calcineurin', 'inhibitors, topical Vitamin A or D analog preparations, or', 'anthralin within 14 days of baseline', 'Exceptions: low potency topical corticosteroids (class I and II,', 'according to European classification for potency of topical', 'corticosteroids) will be allowed as therapy for the face, groin,', \"axillae in accordance with the manufacturer's suggested usage\", 'dose', 'Page 4 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'Psoralen plus ultraviolet A radiation (PUVA), ciclosporin,', 'acitretin, alitretinoin, alefacept (Amevive), anakinra (Kineret),', 'systemic corticosteroids, methotrexate, fumaric acids or any', 'other systemic anti-psoriasis therapy within 28 days of baseline', 'Prior (within the last 2 years) or concomitant use of antipsoriatic', 'biologic therapy with Tumor Necrosis Factor (TNF)-a blocker', 'and / or ustekinumab and / or ixekizumab and / or secukinumab', 'and / or brodalumab and / or guselkumab', 'Concomitant use of strong cytochrome P450 3A4 (CYP3A4)', 'enzyme', 'inductors', '(e.g.', 'rifampicin,', 'phenobarbital,', \"carbamazepin, phenytoin and St. John's wort)\", 'Use of an investigational drug within 4 weeks prior to baseline', 'or', '5 pharmacokinetic/pharmacodynamics half-lives (whichever', 'is longer)', 'Prior treatment with apremilast / Otezla\u00ae', 'Receipt of any live (attenuated) vaccine within 28 days prior to', 'baseline.', 'Concomitant use of any other phosphodiesterase 4 inhibitor', 'Patients with hereditary problems of galactose intolerance, lapp', 'lactase deficiency or glucose-galactose malabsorption', 'For patients with skin biopsy samples taken: patients with', 'clinically relevant coagulation disorders or medication or known', 'hypersensitivity against local anesthetics', 'Investigational', 'Apremilast (Otezla)', 'Medicinal Product', '(Including Placebo', 'and Active', 'Comparator, If Any)', 'Dosage and', 'Apremilast BID, orally', 'Administration', 'Day 1: 10 mg in morning', 'Day 2: 10 mg in morning and 10 mg in evening', 'Day 3: 10 mg in morning and 20 mg in evening', 'Day 4: 20 mg in morning and 20 mg in evening', 'Day 5: 20 mg in morning and 30 mg in evening', 'Day 6 and thereafter: 30 mg twice daily', 'Concomitant', 'Required concomitant medication (except those listed under', 'Treatment', 'exclusion criteria) for the treatment of concomitant diseases and', 'not known to interfere with the study drug or to mask the effect of', 'the study drug, is unrestricted and may be continued during the', 'study.', 'Low potency topical corticosteroids (class I and II, according to', 'European classification for potency of topical corticosteroids) will', 'be allowed as background therapy for the treatment of the face,', \"axillae, and groin in accordance with the manufacturer's suggested\", 'usage during the course of the study except for lesions selected for', 'clinical evaluations.', 'An unmedicated skin moisturizer (without urea) is permitted for', 'body lesions only. Patients should not use the unmedicated skin', 'moisturizer within 12 hours prior to the clinic visit on lesions', 'selected for clinical evaluations.', 'Page 5 of 75']\n\n###\n\n", "completion": "END"}